Demographics and disease characteristics of psoriasis patients enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR).Citation formats

  • External authors:
  • K Mcelhone
  • J N W N Barker
  • A D Burden
  • A D Ormerod
  • N J Reynolds
  • C H Smith
  • C E M Griffiths

Standard

Demographics and disease characteristics of psoriasis patients enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR). / Iskandar, I Y K; Ashcroft, D M; Warren, R B; Yiu, Z Z N; Mcelhone, K; Lunt, M; Barker, J N W N; Burden, A D; Ormerod, A D; Reynolds, N J; Smith, C H; Griffiths, C E M.

In: The British journal of dermatology, Vol. 173, No. 2, 07.09.2015, p. 510-518.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Iskandar, I Y K ; Ashcroft, D M ; Warren, R B ; Yiu, Z Z N ; Mcelhone, K ; Lunt, M ; Barker, J N W N ; Burden, A D ; Ormerod, A D ; Reynolds, N J ; Smith, C H ; Griffiths, C E M. / Demographics and disease characteristics of psoriasis patients enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR). In: The British journal of dermatology. 2015 ; Vol. 173, No. 2. pp. 510-518.

Bibtex

@article{ae50de6edb174e089df8d25a465d9726,
title = "Demographics and disease characteristics of psoriasis patients enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR).",
abstract = "BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-severe psoriasis in the UK and Republic of Ireland. OBJECTIVES: To describe the demographics, disease severity and co-morbidities of psoriasis patients on enrolment into BADBIR, and to highlight differences in those commencing biologic compared to conventional systemic therapies. METHOD: Baseline data were collected from 151 Dermatology departments in the UK and Republic of Ireland. Descriptive analysis was conducted.RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065(60{\%}) received biologics of whom 52.8{\%} received adalimumab, 24.6{\%} etanercept, 18.7{\%} ustekinumab and 3.9{\%} infliximab. In the comparator cohort 44.1{\%} received methotrexate, 23.1{\%} ciclosporin, 18.0{\%} acitretin and 7.6{\%} fumaric acid esters. 4897(58{\%}) were male. Patients on biologics had a higher mean (±SD) age and disease duration than patients on conventional systemic therapies (46.3±12.7vs.44.3±14.3 years; 23.0±12.6vs.19.0±13.4 years, respectively; p1 co-morbidity. The most frequent co-morbidities were obesity (42.1{\%}), hypertension (25.7{\%}), depression (22.1{\%}) and psoriatic arthritis (17.1{\%}). CONCLUSION: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies. This article is protected by copyright. All rights reserved.",
author = "Iskandar, {I Y K} and Ashcroft, {D M} and Warren, {R B} and Yiu, {Z Z N} and K Mcelhone and M Lunt and Barker, {J N W N} and Burden, {A D} and Ormerod, {A D} and Reynolds, {N J} and Smith, {C H} and Griffiths, {C E M}",
year = "2015",
month = "9",
day = "7",
doi = "10.1111/bjd.13908",
language = "English",
volume = "173",
pages = "510--518",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "John Wiley & Sons Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Demographics and disease characteristics of psoriasis patients enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

AU - Iskandar, I Y K

AU - Ashcroft, D M

AU - Warren, R B

AU - Yiu, Z Z N

AU - Mcelhone, K

AU - Lunt, M

AU - Barker, J N W N

AU - Burden, A D

AU - Ormerod, A D

AU - Reynolds, N J

AU - Smith, C H

AU - Griffiths, C E M

PY - 2015/9/7

Y1 - 2015/9/7

N2 - BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-severe psoriasis in the UK and Republic of Ireland. OBJECTIVES: To describe the demographics, disease severity and co-morbidities of psoriasis patients on enrolment into BADBIR, and to highlight differences in those commencing biologic compared to conventional systemic therapies. METHOD: Baseline data were collected from 151 Dermatology departments in the UK and Republic of Ireland. Descriptive analysis was conducted.RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065(60%) received biologics of whom 52.8% received adalimumab, 24.6% etanercept, 18.7% ustekinumab and 3.9% infliximab. In the comparator cohort 44.1% received methotrexate, 23.1% ciclosporin, 18.0% acitretin and 7.6% fumaric acid esters. 4897(58%) were male. Patients on biologics had a higher mean (±SD) age and disease duration than patients on conventional systemic therapies (46.3±12.7vs.44.3±14.3 years; 23.0±12.6vs.19.0±13.4 years, respectively; p1 co-morbidity. The most frequent co-morbidities were obesity (42.1%), hypertension (25.7%), depression (22.1%) and psoriatic arthritis (17.1%). CONCLUSION: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies. This article is protected by copyright. All rights reserved.

AB - BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-severe psoriasis in the UK and Republic of Ireland. OBJECTIVES: To describe the demographics, disease severity and co-morbidities of psoriasis patients on enrolment into BADBIR, and to highlight differences in those commencing biologic compared to conventional systemic therapies. METHOD: Baseline data were collected from 151 Dermatology departments in the UK and Republic of Ireland. Descriptive analysis was conducted.RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065(60%) received biologics of whom 52.8% received adalimumab, 24.6% etanercept, 18.7% ustekinumab and 3.9% infliximab. In the comparator cohort 44.1% received methotrexate, 23.1% ciclosporin, 18.0% acitretin and 7.6% fumaric acid esters. 4897(58%) were male. Patients on biologics had a higher mean (±SD) age and disease duration than patients on conventional systemic therapies (46.3±12.7vs.44.3±14.3 years; 23.0±12.6vs.19.0±13.4 years, respectively; p1 co-morbidity. The most frequent co-morbidities were obesity (42.1%), hypertension (25.7%), depression (22.1%) and psoriatic arthritis (17.1%). CONCLUSION: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies. This article is protected by copyright. All rights reserved.

U2 - 10.1111/bjd.13908

DO - 10.1111/bjd.13908

M3 - Article

VL - 173

SP - 510

EP - 518

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 2

ER -